• Title of article

    Skeletal safety of tiludronate

  • Author/Authors

    R. M. Neer، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1995
  • Pages
    3
  • From page
    501
  • To page
    503
  • Abstract
    The medical uses of bisphosphonates derive from their exceptional ability to inhibit bone resorption. However, bone resorption is essential for the healing of fractures, the repair of microscopic fatigue cracks in bone, and the internal reorientation of trabecular and cortical bone in response to altered mechanical strains. In theory, overdose with bisphosphonates might interfere with the repair of fractures or weaken bone strength (by forcing bones to accumulate and propagate fatigue cracks or by abolishing the skeletonʹs adaptive powers). Regulatory agencies (particularly in the USA) have, therefore, set comprehensive and stringent safety criteria before the marketing of bisphosphonates can be approved. Some bisphosphonates can also inhibit bone mineralization, alter hepatic function, or cause gastritis/ esophagitis. The safety profile of tiludronate will be described from this perspective, emphasizing the results of prolonged treatment in animals, and studies in humans.
  • Keywords
    Tiludronate , Resorption , fractures , Pagetיs disease , Cortical , mineralization , Trabecular
  • Journal title
    Bone
  • Serial Year
    1995
  • Journal title
    Bone
  • Record number

    489952